The most advanced oral pain relief for canine OA1,2
Galliprant is the 1st and only piprant that precisely targets the EP4 receptor, the primary mediator of canine osteoarthritis (OA) pain and inflammation.2,3
Disrupt the cycle of pain and progression of disease, while protecting dogs from the side effects seen with COX-inhibition.4-6
How have NSAIDs evolved over the years?
Vets prescribe Galliprant for daily use 68% more than traditional NSAIDs7
Discover how Galliprant works
A flexible option for dogs diagnosed with OA in the prime of their lives!
Galliprant is the only piprant recommended as part of a multimodal approach to OA management.
- Most dogs can be dosed once a day with a whole or half tablet
- A simple, once-daily, chewable tablet that fits into daily routine
- No fixed monitoring schedule required on label*. Any monitoring can be fitted around the owner and pet’s needs
Galliprant was well tolerated over 9 months in a target animal safety study at doses equivalent to 15x the target dose. No treatment was stopped or dogs removed from the study due to adverse events.4
DISCOVER ALL THE BENEFITS OF MYELANCO
Galliprant Video: A Brief Introduction to Galliprant
A 4-minute introduction to Galliprant, a first-in-class Piprant for Canine Osteoarthritis
*as field studies were to 28 days, longer-term treatment should be considered carefully & regular monitoring undertaken by the vet. Refer to Galliprant SPC section 4.9.
- Pye C, et al. J Small Anim Pract. 2022;63:721–738.
- Kirkby Shaw K. Oral presentation. American College of Veterinary Internal Medicine Forum, 3–6 June 2015, Indianapolis IN, USA.
- Kirkby Shaw K, et al. Vet Med Sci. 2016;2:3–9.
- Rausch-Derra LC, et al. Am J Vet Res 2015;76:853–859.
- Pfeifer JM, et al. J Vet Emerg Crit Care. 2022;32:764–768.
- Rausch-Derra L, et al. J Vet Intern Med 2016;30:756–763.
- Elanco Data on File. Market research conducted in the UK and Europe on NSAID use by 1093 users from December 2, 2021 to January 20, 2022 by Inspired Health Inc.
